Pharmaceutical Investing Acerus Updates on Temporary Unavailability of NATESTO in Canada and South Korea
Pharmaceutical Investing VIDEO - Acerus Pharma CEO: Keeping Focus on Drug Delivery Tech, Not Cannabis
Acerus Receives Notice of Deficiency – Withdrawal Letter from Health Canada Regarding Gynoflor Application
Pharmaceutical Investing Acerus Announces Results of Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil
Pharmaceutical Investing Acerus Provides Update on Continuing Commercial and R&D Achievements for NATESTO®
Pharmaceutical Investing Acerus Announces Expansion of NATESTO® Agreement with medac and the Submission of NATESTO® Dossier in Europe
